Prestige Consumer Healthcare Inc. reported record financial results for its third fiscal quarter ended December 31, 2024. The company achieved reported revenues of $290.3 million, an increase of 2.7% from $282.7 million in the prior year's third quarter.
Diluted earnings per share for the third quarter of fiscal 2025 reached $1.22, up from $1.06 in the comparable prior-year period. This performance was driven by strong growth in the International OTC segment, which saw an 11.3% revenue increase, or 8.3% excluding foreign currency effects.
The company's North American OTC Healthcare segment experienced a 1.0% revenue increase, supported by growth in GI and Dermatologicals categories. Prestige Consumer Healthcare also raised its full-year fiscal 2025 earnings outlook, attributing the improvement to strong free cash flows, reduced interest expense, and fewer outstanding shares.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.